California (CA) Litigation CLE Course Catalog

Connect with distinguished asbestos litigation professionals Justinian C. Lane and Timothy L. Krippner as they share their knowledge on how to effectively manage the ever-changing dynamics of asbestos claims and lawsuits. Expert panelists will also provide insights into the most current and trending issues affecting asbestos litigation along with groundbreaking tips on how to curtail the never-ending asbestos crisis.

Over the years, the number of class action lawsuits has significantly grown in both federal and state courts. As regulatory developments continue to emerge and impact litigation practices, practitioners are confronted with significant challenges. Hence, they must keep themselves abreast of any development in this field of law. Likewise, implementing a sound class action strategy is critical to dodge any litigation pitfall. In this CLE program, securities consulting practitioner Brendan J. Rudolph and leading class action attorney Greg Coleman will provide an overview of the most critical and relevant class action developments. The speakers will also discuss the latest updates and key issues involving data privacy, product liability, and mislabeling and contamination cases.

A non-compete agreement is crucial for protecting a company’s trade secrets and other valuable assets from employees who leave the business. However, some organizations fail to include legitimate restrictions for employees’ conduct even after their employment ended, exposing them to risks. More so, the potential for misappropriation or theft of trade secrets. This underscores the need for businesses and their counsel to be well-versed in drafting sound non-compete agreements and be abreast of emerging developments to be able to structure preventive measures and mitigate potential risks. Listen as a panel of key thought leaders and distinguished experts provide the audience with a comprehensive discussion on utilizing non-compete agreements to ensure trade secret protection. Speakers, among other things, will also offer practical tips and best practices to avoid pitfalls.

In this program, a panel of key thought leaders will provide an in-depth discussion of the critical and recurrent issues surrounding trade secret litigation. Speakers will also offer new defense strategies to ensure success in this type of lawsuit.

In this program, recognized thought leaders in international trade and compliance Cyrus T. Frelinghuysen (Greenberg Traurig, LLP) and Tony V. Pezzano (Offit Kurman) will discuss the significant and latest developments surrounding ITC litigation. The speakers will also share practical litigation tools and techniques to ensure success in this type of lawsuit.

Listen as experienced practitioners in ESOP-related transactions Mr. Eli Burriss (Katten Muchin Rosenman LLP) and Mr. Scott Adamson (ArentFox Schiff LLP) provide the audience with the recent trends and developments in employee stock ownership plan (ESOP) as well as its implications in litigation matters. Speakers, among other things, will offer practical tips and strategies to avoid non-compliance and potential lawsuits.

In this program, experienced class action lawyers Jennifer A. Riley (Duane Morris LLP) and Gregory P. Abrams (Faegre Drinker Biddle & Reath LLP) will delve into an in-depth analysis of the current trends and recent court rulings involving the Biometric Information Privacy Act (BIPA). The speakers will also provide the audience with practical strategies for bringing out the best in these lawsuits in a rapidly evolving legal climate.

Class actions remain at the forefront of in-house counsel’s concerns and top legal spend. In this program, highly recognized practitioners in class action litigation Joseph A. Apatov (McGlinchey Stafford PLLC) and Bethany G. Lukitsch (BakerHostetler) will discuss the significant and latest issues surrounding consumer class actions. Speakers will also provide the audience with practical strategies to mitigate class action risks.

As the COVID-19 crisis stretches into its third year, brands and generic drug companies will likely see the impact of continued regulatory developments in the Hatch-Waxman space. Moreover, recent notable cases further reveal key takeaways and unresolved issues which drug companies should be wary of. Among the salient developments involve changes in venue for a Hatch-Waxman Act case — highlighting the need for concerned practitioners to stay close to the venue issue as it remains to be a focus of the Federal courts. In this program, a panel of key thought leaders and practitioners will offer an in-depth look at the critical developments and issues surrounding Hatch-Waxman litigation. This course will provide helpful insights to help your company deal with patent challenges.